youtube.com/watch?v=TC-9nE… Very nice interview with David Regan, CEO, and Carman Giacomantonio, MD, MSc, FRCSC, CMO of Sona Nanosystems, Inc. Great perspective on why their THT/Gold Nanorod technology is so exciting and the role of $BIOV $BVAXF #DPX in further enhancing immune

Together with researchers from Laval University, $BIOV $BVAXF has submitted an abstract on the phase 1 data for #DPX-surMAGE for presentation at the European Society for Medical Oncology (#ESMO) taking place in Berlin this October 2025. The annual ESMO Congress is attended by

$BIOV $BVAXF is pleased to be attending the #BARDA RRPV | Rapid Response Partnership Vehicle 2025 General Members Meeting Aug 26-27 in Arlington VA. A great opportunity for networking and collaboration with other members of RRPV and representatives from the Department of Health and Human Services.

Join us in welcoming former #Sanofi senior executive Dr. James Tartaglia to the $BIOV $BVAXF Board. Dr Tartaglia is a globally recognized #vaccine R&D leader with >30 years of experience in biopharma. As Global Head of Vaccine Development & Life Cycle Management at Sanofi, he

prnewswire.com/news-releases/… Congratulations to our licensee, SpayVac-for-Wildlife, Inc., on their #immunocontraceptive single-dose efficacy study published in the European Journal of Wildlife Research---and initiation of #SpayVac registration!

BIOV research collaborator Sona Nanotech achieves remarkable 80% response rate---with 60% complete responders---following their THT therapy in late-stage melanoma patients not responding to standard immunotherapy. We look forward to further advancing our research collaboration

newsfilecorp.com/release/274359… $BIOV is now eligible to be traded on the Canadian Securities Exchange using the Market-on-Close (MOC) facility. Stocks are eligible based on the exchange's decision to include them in this feature, which aims to centralize liquidity for certain

thenewswire.com/press-releases… BioVaxys welcomes Marianne Stanford, PhD, as Scientific Advisor. Formerly VP of R&D at IMV Inc., she advanced the DPX™ vaccine platform,and is named inventor on multiple patents related to the DPX platform including patents on DPX mRNA compositions and

Our Founder, President, and COO, Kenneth Kovan, recently sat down with Ricki Lee from The Watchlist to discuss the positive Phase 1 results for maveropepimut-S (MVP-S). The interview highlights the strong immune response achieved with MVP-S in hormone

2025 in Review: A Year of Momentum & A Bright Path Ahead As 2025 draws to a close, we at BioVaxys are proud to reflect on a year of meaningful progress and strategic advancement. A major milestone was the successful integration of the powerful DPX™ platform into the heart of

Dr. Sasha Stanton, MD, PhD, Principal Investigator at Providence Cancer Center, is more than a scientist; she is also a breast cancer patient. This personal connection drives her passion for advancing better treatments. Watch her discuss the encouraging Phase 1 results of

BioVaxys Technology Corp. is pleased to announce our active participation in the Biomedical Advanced Research and Development Authority’s (BARDA) Request for Information (RFI) for transformative “New Vaccine Platforms.” This RFI seeks technologies that enable rapid, efficient

Join us Thursday @ 4:15PM EST for a live investor Q&A with BioVaxys Technology Corp.! $BIOV 🇨🇦 $BVAXF 🇺🇸 x.com/i/spaces/1MYxN…

We are very pleased to have been invited back to CEPI (the Coalition for Epidemic Preparedness Innovations) next month for a deeper scientific discussion of our DPX educating platform. CEPI cepi.net is a global partnership working to accelerate the development of